Dr. Panagiotis J. Vlachostergios MD PhD is an American board of Internal Medicine/Medical Oncology-certified Assistant Professor of Clinical Medicine in the Department of Medicine, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, New York, NY, USA. Dr. Vlachostergios received his Ph.D. in Cancer Biology in 2013. He completed his Internal Medicine Residency at New York University School of Medicine, Langone Hospital and his Hematology and Medical Oncology Clinical Fellowship at Weill Cornell Medical College, New York Presbyterian Hospital. He has further completed post-doctoral training in Genomic Cancer Risk Assessment (City of Hope Comprehensive Cancer Center); Genetics and Genomics (Stanford University); Genetics, Cancer Genomics and Precision Oncology (Harvard Medical School); Immunology and Immuno-Oncology (Harvard Medical School); and Clinical Research (Weill Cornell Clinical and Translational Science Center). Dr. Vlachostergios has published more than 100 international peer-reviewed articles and authored several book chapters and abstracts. His research has been highly cited, and he is a recipient of prestigious awards from the American Society of Clinical Oncology, European Society of Medical Oncology, Society for Translational Oncology, American Federation for Medical Research, Bladder Cancer Advocacy Network, and others. His basic, translational and clinical research is mainly focused on genitourinary cancers, lung, breast and CNS tumors. He has presented his works at many prestigious conferences, including ASCO, ESMO, AACR, EACR, EAU, AUA and forged strong relationships and research collaborations with renowned cancer experts and leaders across the US and Europe. Dr. Panagiotis J. Vlachostergios MD PhD is an American board of Internal Medicine/Medical Oncology-certified Assistant Professor of Clinical Medicine in the Department of Medicine, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, New York, NY, USA. Dr. Vlachostergios received his Ph.D. in Cancer Biology in 2013. He completed his Internal Medicine Residency at New York University School of Medicine, Langone Hospital and his Hematology and Medical Oncology Clinical Fellowship at Weill Cornell Medical College, New York Presbyterian Hospital. He has further completed post-doctoral training in Genomic Cancer Risk Assessment (City of Hope Comprehensive Cancer Center); Genetics and Genomics (Stanford University); Genetics, Cancer Genomics and Precision Oncology (Harvard Medical School); Immunology and Immuno-Oncology (Harvard Medical School); and Clinical Research (Weill Cornell Clinical and Translational Science Center). Dr. Vlachostergios has published more than 100 international peer-reviewed articles and authored several book chapters and abstracts. His research has been highly cited, and he is a recipient of prestigious awards from the American Society of Clinical Oncology, European Society of Medical Oncology, Society for Translational Oncology, American Federation for Medical Research, Bladder Cancer Advocacy Network, and others. His basic, translational and clinical research is mainly focused on genitourinary cancers, lung, breast and CNS tumors. He has presented his works at many prestigious conferences, including ASCO, ESMO, AACR, EACR, EAU, AUA and forged strong relationships and research collaborations with renowned cancer experts and leaders across the US and Europe.